Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CORT

Corcept Therapeutics Incorporated

Healthcare | Biotechnology

No licensed closing price on file for CORT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.42

Corcept Therapeutics Incorporated (NASDAQ: CORT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 00:32 UTC.

What Corcept Therapeutics Incorporated does

The company is a commercial-stage pharmaceutical firm that discovers and develops medications to treat serious endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of cortisol, a hormone essential to the body's stress response and metabolism. The company currently markets Korlym and an authorized generic version in the United States for treating hypercortisolism (Cushing's syndrome), a condition caused by abnormally high cortisol levels that can affect multiple organ systems and be lethal if untreated.

Summarized from Corcept Therapeutics Incorporated’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.42
Return on equity15.38%

Revenue, margins & earnings

FY2021 Net income: $113MFY2021 Taxes & interest: $12MFY2021 Operating costs: $242M$366MFY2021FY2022 Net income: $101MFY2022 Taxes & interest: $11MFY2022 Operating costs: $289M$402MFY2022FY2023 Net income: $106MFY2023 Operating costs: $375M$482MFY2023FY2024 Revenue: $675M — margin split not shown (non-operating gains)$675MFY2024FY2025 Revenue: $761M — margin split not shown (non-operating gains)$761MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16DirectorSale-300$34.9K
  • 2026-10-16DirectorSale-6,654$761.7K
  • 2026-10-16DirectorSale-3,046$351.5K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Corcept Therapeutics Incorporated do?

The company is a commercial-stage pharmaceutical firm that discovers and develops medications to treat serious endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of cortisol, a hormone essential to the body's stress response and metabolism.

When did CORT last file with the SEC?

Corcept Therapeutics Incorporated's most recent SEC filing on record is a 8-K filed 2026-06-17. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 00:32 UTC. This page is also available as JSON at /api/data?ticker=CORT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CORT and 5,000+ tickers.

Create a free account — keep CORT
For your agent
GET /api/data?ticker=CORT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt